Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 2, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 2, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/2/14 - "Nanoparticle Drug Carrier, Pharmaceutical Composition and Manufacturing Method Thereof" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Gene Therapy Weekly A patent application by the inventors Chen, San-Yuan; Li, Wei-Ming, filed on September 25, 2013, was made available online on September 18, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Chiao
10/2/14 - ABPI comments on recent articles regarding the relationship between industry and patient groups
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK. Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are re
10/2/14 - Arena Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 2 Arena Pharmaceuticals, San Diego, has been assigned a patent developed by Jeffrey Smith, San Diego, and Brian Smith, San Diego, for 5 HT.sub.2C receptor modulators. The patent application was filed on Sept. 14, 2012. Written by Kusum Sangma; edited by Jaya Anand.
10/2/14 - Baxter to Open New Global Innovation and R&D Center near Boston for Its Biopharmaceuticals Business [Professional Services Close - Up]
Baxter International Inc. reported plans to form a new global innovation and research and development center in Cambridge, Mass., for Baxter's biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta Inc. in mid-2015. Joining this unmatched biotech community is an important step, "said Ludwig
10/2/14 - Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion
Release date- 01102014- Leverkusen,- Bayer has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck& Co., Inc., Whitehouse Station, New Jersey. Pro forma sales of the combined businesses in 2013 amounted to USD 7.4 billion, with Merck& Co., Inc.' s business contributing approximately USD 2.2 billion. The a
10/2/14 - Biofrontera Gets Positive Results From Ameluz US Clinical Trials
LONDON- Biofrontera AG Thursday said it has completed the clinical programme for US approval of its Ameluz product, with trials confirming the efficacy and safety of the treatment. In addition, only 38% of the patients required the second treatment, Biofrontera said. Along with the phase 3 trial, Biofrontera said the US Food and Drug Administration
10/2/14 - Cydex Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 2 Cydex Pharmaceuticals, San Diego, has been assigned a patent developed by Gerold L. Mosher, Kansas City, Missouri, James D. Pipkin, Lawrence, Kansas, and Douglas B. Hecker, Liberty, Missouri, for "sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof." The patent application was filed on Sept. 23, 2
10/2/14 - Ebola Vaccines Are Being Expedited [Yerepouni Daily News (Armenia)]
International experts want a fully tested and licensed Ebola vaccine scaled up for mass use in the near future, according to a recent World Health Organization meeting. The first vaccine is developed by the U.S. National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. That vaccine is currently undergoing a human-safety trial at th
10/2/14 - FDA Clears NEMARIS' Next-Generation SURGIMAP 2.0 Software for Personalized Spinal Implants [Professional Services Close - Up]
SURGIMAP 2.0 includes the UNiD plug in, jointly developed with one of the company's strategic partners, MEDICREA,, a company that specializes in the development of surgical technologies for the treatment of spinal pathologies. The UNiD plug in is embedded into the SURGIMAP 2.0 software interface, and provides surgeons an option for planning and ord
10/2/14 - Genentech, Array BioPharma Assigned Patent
ALEXANDRIA, Va., Oct. 2 Genentech, South San Francisco, California, and Array BioPharma, Boulder, Colorado, have been assigned a patent developed by 10 co-inventors for "pyrimidyl cyclopentanes as Akt protein kinase inhibitors." The co-inventors are Josef R. Bencsik, Boulder, Colorado, James F. Blake, Boulder, Colorado, Nicholas C. Kallan, Boulde
10/2/14 - Genentech, Array BioPharma Assigned Patent for Pyrimidyl Cyclopentanes as AKT Protein Kinase Inhibitors
ALEXANDRIA, Va., Oct. 2 Genentech, South San Francisco, California, and Array BioPharma, Boulder, Colorado, have been assigned a patent developed by 14 co-inventors for "pyrimidyl cyclopentanes as AKT protein kinase inhibitors." The co-inventors are Ian S. Mitchell, Lafayette, Colorado, James F. Blake, Longmont, Colorado, Rui Xu, Longmont, Colora
10/2/14 - Global Idiopathic (Essential) Hypertension Clinical Trials Review 2014 - Featuring the Top 10 Companies and 9 Institutues
Dublin- Research and Markets has announced the addition of the "Idiopathic Hypertension Global Clinical Trials Review, H2, 2014" report to their offering. -Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along wi
10/2/14 - Gov't website for doc payments not up to snuff
WASHINGTON Although it's called "Open Payments," the government's new website doesn't make it easy to find out whether your doctor is getting freebies, travel or other financial benefits from drug companies and medical device manufacturers. However, an Associated Press analysis found significant problems, including large chunks of missing inform
10/2/14 - Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results
Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650. The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical trial that tested the efficacy and safety of ITCA 650 in patients with type 2 diabetes against placebo. The HBL study also showed the
10/2/14 - Isis Pharmaceutical Assigned Patent
ALEXANDRIA, Va., Oct. 2 Isis Pharmaceutical, Carlsbad, California, has been assigned a patent developed by Eric E. Swayze, Encinitas, California, and Andrew M. Siwkowski, Carlsbad, California, for "oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity." The patent application was filed on April 3, 2009. Written by Balki
10/2/14 - Isis Pharmaceuticals Assigned Patent for Substituted 2'-amino and 2'-thio-Bicyclic Nucleosides and Oligomeric Compounds Prepared Therefrom
ALEXANDRIA, Va., Oct. 2 Isis Pharmaceuticals, Carlsbad, California, has been assigned a patent developed by Punit P. Seth, Carlsbad, California, Thazha P. Prakash, Carlsbad, California, and Eric E. Swayze, Encinitas, California, for "substituted 2'- amino and 2'- thio-bicyclic nucleosides and oligomeric compounds prepared therefrom." The patent a
10/2/14 - Judges uphold Alameda County drug disposal law [Contra Costa Times]
Oct. 01 SAN FRANCISCO Drug manufacturers will have to pay to collect and discard unwanted prescription pills in Alameda County after a federal appeals court rejected an industry challenge to the nation's first drug take-back law. "We certainly hope that this is the end of it," said Donna Ziegler, Alameda County chief counsel, noting that the c
10/2/14 - PAREXEL Biopharmaceutical Statistical Sourcebook 2014/2015
By a News Reporter-Staff News Editor at Gene Therapy Weekly Research and Markets has announced the addition of the "PAREXEL Biopharmaceutical Statistical Sourcebook 2014/ 2015" report to their offering. PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2014/ 2015 is the leading resource for statistics, trends, and proprietary market intelligen
10/2/14 - Philips Electronics $650 Million Masimo Lawsuit is in Front of Jury; Keryx declares Issuance of a New U.S. Patent for Ferric Citrate
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 1, 2014.{ nfg} Jurors immediately began debating whether Royal Philips NV, the world s biggest lighting company, ought pay up more than $650 million in damages to Masimo Corporation for infringing patents covering technology used in fingerti
10/2/14 - Portola Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 2 Portola Pharmaceuticals, South San Francisco, California, has been assigned a patent developed by six co-inventors for "benzamides and nicotinamides as Syk modulators." The co-inventors are Zhaozhong J. Jia, San Mateo, California, Yonghong Song, Foster City, California, Qing Xu, Foster City, California, Brian Kane, Oakland
10/2/14 - Regeneron Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Oct. 2 Regeneron Pharmaceuticals, Tarrytown, New York, has been assigned a patent developed by five co-inventors for a "method for genetically modifying isolated non-human mammalian cell by homologous recombination." The co-inventors are Aris N. Economides, Tarrytown, New York, Andrew J. Murphy, Croton-on-Hudson, New York, David
10/2/14 - Regeneron Pharmaceuticals, Yale University Assigned Patent
ALEXANDRIA, Va., Oct. 2 Regeneron Pharmaceuticals, Tarrytown, New York, Yale University, New Haven, Connecticut, and Institute for Research in Biomedicine, Bellinzona, Switzerland, have been assigned a patent developed by seven co-inventors for a humanized M-CSF mice. The co-inventors are Andrew J. Murphy, Croton-on-Hudson, New York, Sean Stevens
10/2/14 - Researchers Submit Patent Application, "Applicator", for Approval
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventors Ueta, Masahiro; Sakaguchi, Ryouhei; Takei, Ryouji; Sasama, Katsumi; Taguchi, Katsuya, filed on July 4, 2012, was made available online on September 18, 2014. The patent's assignee is K
10/2/14 - Researchers Submit Patent Application, "Pharmaceutical Warning System and Method", for Approval
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Huntley, Susan B., filed on March 9, 2013, was made available online on September 18, 2014. No. 4,607,747, entitled,' Packaging for a Product as Well as Use of the Same,' issued to Stei
10/2/14 - Researchers Submit Patent Application, "Re-Useable Injector Device for Syringe", for Approval
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Cowe, Toby, filed on October 8, 2013, was made available online on September 18, 2014. The patent's assignee is Teva Pharmaceutical Industries Limited. News editors obtained the followi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415